No Low-Hanging Fruit for Medical Device Entrepreneurs
In a speech at Windhover's December 2000 Start-Up Symposium, Novoste chairman Tom Weldon argued that device start-ups will be fewer and riskier. Both the FDA and physicians are demanding trials that prove clinical efficacy, raising the cost and therefore the risk of starting new companies. That means these firms will have to target larger markets, which by their very nature will require a change in medical practice and thus also a more expensive selling effort. Unless companies go after products that can sell a minimum of $500 million annually, financiers won't be able to justify the investment required to get these companies off the ground.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.